Skip to main content

12 Result(s)

within H. Glimm Remove this filter

and

  1. No Access

    Article

    The German Network for Personalized Medicine to enhance patient care and translational research

    A. L. Illert, A. Stenzinger, M. Bitzer, P. Horak, V. I. Gaidzik… in Nature Medicine (2023)

  2. No Access

    Article

    Personalisierte Onkologie

    Innovative „Next-generation-sequencing“(NGS)-Technologien und umfangreiche genomische Untersuchungen großer Patientenkohorten haben zu vielversprechenden personalisierten Therapiestrategien auf der Basis molek...

    C. Heining, P. Horak, S. Gröschel, H. Glimm, Prof. S. Fröhling in Der Radiologe (2017)

  3. No Access

    Article

    The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

    Despite therapeutic advances, multiple myeloma (MM) remains an incurable disease, predominantly because of the development of drug resistance. The activator protein-1 (AP-1) transcription factor family has bee...

    F Fan, M H Bashari, E Morelli, G Tonon, S Malvestiti, S Vallet, M Jarahian… in Leukemia (2017)

  4. No Access

    Article

    Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling

    Activating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations in the D594F595G596 motif cooperate with RAS via par...

    M Kordes, M Röring, C Heining, S Braun, B Hutter, D Richter, C Geörg, C Scholl… in Leukemia (2016)

  5. No Access

    Article

    NDRG1 prognosticates the natural course of disease in WHO grade II glioma

    There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1, codeletion of 1p/19q and promoter hypermethylation of O ...

    J. Blaes, M. Weiler, F. Sahm, B. Hentschel, M. Osswald… in Journal of Neuro-Oncology (2014)

  6. No Access

    Article

    What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?

    Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major clinical challenge, and disagreement on the optimal ...

    L. Sellner, S. Denzinger, S. Dietrich, H. Glimm… in Current Hematologic Malignancy Reports (2013)

  7. No Access

    Article

    10-Year stability of clinical-grade serum-free γ-retroviral vector-containing medium

    More than 10 years ago, we developed an efficient protocol for serum-free retroviral transduction of human hematopoietic stem cells derived from mobilized peripheral blood. After upscaling of the methodology, ...

    F Herbst, C R Ball, O Zavidij, S Fessler, M Schmidt, H Veelken, C von Kalle… in Gene Therapy (2011)

  8. Article

    Open Access

    Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

    Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list. Transarterial chemoem...

    K Hoffmann, H Glimm, B Radeleff, G Richter, C Heining, I Schenkel… in BMC Cancer (2008)

    Download PDF (295 KB) View Article

  9. No Access

    Article

    Hämatopoetische Stammzelltherapie

    In den letzten Jahren sind deutliche Fortschritte im Verständnis der Regulation hämatopoetischer Stammzellen (HSZ) und ihrer Bedeutung für die normale Blutbildung im Knochenmark erzielt worden. Durch eine Reih...

    C. Buske, H. Glimm, PD Dr. M. Feuring-Buske in Der Internist (2006)

  10. No Access

    Article

    Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease

    Xenograft models of chronic phase human chronic myeloid leukemia (CML) have been difficult to develop because of the persistence of normal hematopoietic stem cells in most chronic phase CML patients and the la...

    W Eisterer, X Jiang, O Christ, H Glimm, K H Lee, E Pang, K Lambie, G Shaw… in Leukemia (2005)

  11. No Access

    Chapter and Conference Paper

    Hematopoietic Ex Vivo Gene Transfer

    The goal of somatic gene therapy is to therapeutically benefit an individual by transferring genetic information to non—germline cells. Genes can be transferred either to replace the function of a defective ge...

    H. Glimm, C. von Kalle, R. Henschler, R. Mertelsmann in Gene Therapy (1998)

  12. No Access

    Article

    Electrophysiological properties of neurones in cultures from postnatal rat dentate gyrus

    Electrophysiological properties of neurofilament-positive neurones in dissociated cell cultures were prepared at postnatal days 4–5 from rat dentate gyrus and studied using the whole-cell patch-clamp technique...

    H. Glimm, E. Ficker, U. Heinemann in Experimental Brain Research (1996)